日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Application given for gene therapy trials to treat blood disease

By Liu Zhihua | chinadaily.com.cn | Updated: 2021-01-19 14:44
Share
Share - WeChat
A screenshot from EdiGene's official website. [Photo/edigene.com]

Chinese biotech company EdiGene Inc announced on Monday the Center for Drug Evaluation of the China National Medical Products Administration has approved the company's Investigational New Drug application for ET-01, a CRISPR/Cas 9 gene-editing therapy for patients with transfusion dependent β-thalassemia, a blood disease characterized by severe anemia and a lifelong dependence on red blood cell transfusions that can lead to iron overload.

That marks the first gene-editing therapy and the first hematopoietic stem cell therapy IND application approval in China.

The Beijing-based company develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases. Previously, the company announced the acceptance of the IND by CDE on Oct 27, 2020.

Wei Dong, CEO of EdiGene, said the company will roll out phase I clinical trials soon.

"We are embarking on a new journey as a clinical-stage company. We will continue to translate cutting-edge gene-editing technology and advance our pipeline, with a goal of providing better choices for patients in China and around the world," he said.

ET-01 is an investigational, autologous, ex vivo gene-editing therapy. The approved trial of ET-01 is a multicenter, open-label, single arm study designed to assess safety and efficacy in transfusion dependent β-thalassemia patients.

In China, it is estimated there are over 300,000 patients with thalassemia major or thalassemia intermediate. Serious unmet medical needs remain for transfusion dependent β-thalassemia patients today.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 久久久久久免费一区二区三区 | 精品国产一区三区 | 色婷婷久久久 | 黄色在线观看 | 欧美日韩综合精品一区二区三区 | 嫩草影院地址一二三网址 | 久久99国产精品成人欧美 | 国内色综合精品视频在线 | 搡女人视频免费 | 亚洲图片欧洲电影 | 可以免费观看的av | 欧美激情视频一区二区三区在线播放 | 日韩电影免费在线观看中文字幕 | 亚洲美女黄色 | 亚洲日本一区二区三区 | 视频精品一区 | 午夜精品久久久久久久99黑人 | 亚洲精品久久久久久国产精华液 | 久久久精品午夜免费不卡 | 久久av一区二区三区 | 婷婷视频在线观看 | 久久国内精品 | 热99精品| 久久久久久黄 | 日本高清va不卡视频在线观看 | 一级香蕉免费毛片 | 国产a视频| 狠狠干2020| 日韩高清不卡 | 亚洲美女综合 | 久草久草视频 | 日韩中文字幕在线看 | 亚洲精品中文字幕乱码一区二区 | 亚洲综合一二三区 | 国产一级电影网 | 欧美性一区二区三区 | 亚洲人人爱 | 成人av一区二区三区 | 成人在线免费视频观看 | 精品久久久久久久久久 | 欧美一级夜夜爽 |